carteolol has been researched along with Obesity in 1 studies
Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takahashi, H | 1 |
| Nakano, K | 1 |
| Yasuda, T | 1 |
| Komiyama, Y | 1 |
| Murakami, T | 1 |
| Nishimura, M | 1 |
| Nakanishi, T | 1 |
| Sakamoto, M | 1 |
| Nanbu, A | 1 |
| Yoshimura, M | 1 |
1 other study available for carteolol and Obesity
| Article | Year |
|---|---|
Anti-obesity and anti-diabetic effects of carteolol in non-insulin-dependent diabetic mice.
Topics: Adipose Tissue, Brown; Animals; Blood Pressure; Body Weight; Carbohydrate Metabolism; Cardiac Output | 1994 |